Metraipolis › archive › dc_6563d17fafdf

Impact of etonogestrel implant use on T-cell and cytokine profiles in the female genital tract and blood — Europe PMC PMID:32214321

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/32214321
DOI
10.1371/journal.pone.0230473
License (as archived)
CC0-1.0
Archived
2026-11-09T04:21:05.768Z
SHA-256 of the archived text
a4504b2d6803af4db52dff8b2fc99c5dd931ceecde515da54c02d9d578fee57d
Stable URL of this page
https://metraipolis.com/documento/dc_6563d17fafdf

How to cite

Impact of etonogestrel implant use on T-cell and cytokine profiles in the female genital tract and blood — Europe PMC PMID:32214321 — Europe PMC (en), https://europepmc.org/article/MED/32214321 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_6563d17fafdf (Metraipolis archive dc_6563d17fafdf, sha256 a4504b2d6803af4db52dff8b2fc99c5dd931ceecde515da54c02d9d578fee57d)
BibTeX
@misc{dc6563d17fafdf,
  title = {Impact of etonogestrel implant use on T-cell and cytokine profiles in the female genital tract and blood — Europe PMC PMID:32214321},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/32214321},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_6563d17fafdf; sha256 a4504b2d6803af4db52dff8b2fc99c5dd931ceecde515da54c02d9d578fee57d},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32214321. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: While prior epidemiologic studies have suggested that injectable progestin-based contraceptive depot medroxyprogesterone acetate (DMPA) use may increase a woman's risk of acquiring HIV, recent data have suggested that DMPA users may be at a similar risk for HIV acquisition as users of the copper intrauterine device and levonorgestrel implant. Use of the etonogestrel Implant (Eng-Implant) is increasing but there are currently no studies evaluating its effect on HIV acquisition risk. Objective: Evaluate the potential effect of the Eng-Implant use on HIV acquisition risk by analyzing HIV target cells and cytokine profiles in the lower genital tract and blood of adult premenopausal HIV-negative women using the Eng-Implant. Methods: We prospectively obtained paired cervicovaginal lavage (CVL) and blood samples at 4 study visits over 16 weeks from women between ages 18-45, with normal menses (22-35 day intervals), HIV uninfected with no recent hormonal contraceptive or copper intrauterine device (IUD) use, no clinical signs of a sexually transmitted infection at enrollment and who were medically eligible to initiate Eng-Implant. Participants attended pre-Eng-Implant study visits (week -2, week 0) with the Eng-Implant inserted at the end of the week 0 study visit and returned for study visits at weeks 12 and 14. Genital tract leukocytes (enriched from CVL) and peripheral blood mononuclear cells (PBMC) from the study visits were evaluated for markers of activation (CD38, HLA-DR), retention (CD103) and trafficking (CCR7) on HIV target cells (CCR5+CD4+ T cells) using multicolor flow cytometry. Cytokines and chemokines in the CVL supernatant and blood plasma were measured in a Luminex assay. We estimated and compared study endpoints among the samples collected before and after contraception initiation with repeated-measures analyses using linear mixed models. Results: Fifteen of 18 women who received an Eng-Implant completed all 4 study visits. The percentage of CD4+ T cells in CVL was not increased after implant placement but the percentage of CD4+ T cells expressing the HIV co-receptor CCR5 did increase after implant placement (p = 0.02). In addition, the percentage of central memory CD4+ T-cells (CCR7+) in CVL increased after implant placement (p = 0.004). The percentage of CVL CD4+, CCR5+ HIV target cells expressing activation markers after implant placement was either reduced (HLA-DR+, p = 0.01) or unchanged (CD38+, p = 0.45). Most CVL cytokine and chemokine concentrations were not significantly different after implant placement except for a higher level of the soluble lymphocyte activation marker (sCD40L; p = 0.04) and lower levels of IL12p70 (p = 0.02) and G-CSF (p<0.001). In systemic blood, none of the changes noted in CVL after implant placement occurred except for decreases in the percentage CD4 T-cells expressing HLA-DR+ T cells (p = 0.006) and G-CSF (p = 0.02). Conclusions: Eng-Implant use was associated with a moderate increase in the availability of HIV target cells in the genital tract, however the percentage of these cells that were activated did not increase and there were minimal shifts in the overall immune environment. Given the mixed nature of these findings, it is unclear if these implant-induced changes alter HIV risk.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2020 (prima pubblicazione 2020-03-26).
Identificativi: PMID 32214321 · PMCID PMC7098611 · DOI 10.1371/journal.pone.0230473.
Pagina: https://europepmc.org/article/MED/32214321 — https://doi.org/10.1371/journal.pone.0230473. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-09T04:16:58.099Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.